Estadístiques de Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia
Visites totals
| views | |
|---|---|
| Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia | 71 |
Visites totals per mes
| views | |
|---|---|
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
| August 2025 | 0 |
| September 2025 | 0 |
| October 2025 | 1 |
| November 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| newland-ajh-phas.pdf | 91 |
| newland-ajh-phas.pdf(legacy) | 85 |
Vistes principals per país
| views | |
|---|---|
| United States | 55 |
| Spain | 5 |
| Australia | 2 |
| Belgium | 1 |
| Brazil | 1 |
| Belarus | 1 |
| China | 1 |
| Germany | 1 |
| India | 1 |
| Kazakhstan | 1 |
| Mongolia | 1 |
| Malaysia | 1 |
Visites principals per ciutat
| views | |
|---|---|
| San Ramon | 14 |
| Ann Arbor | 6 |
| Boardman | 6 |
| Fairfield | 6 |
| Ashburn | 5 |
| Mountain View | 5 |
| Menlo Park | 3 |
| Barcelona | 2 |
| Altleiningen | 1 |
| Anaheim | 1 |
| Granollers | 1 |
| Marietta | 1 |
| Pinjarra | 1 |
| Redwood City | 1 |
| Sacramento | 1 |
| San Diego | 1 |
| Shah Alam | 1 |
| Shenzhen | 1 |
| Thane | 1 |
| Ulaanbaatar | 1 |
| Vitebsk | 1 |